Suleyman Yildirim

Dr. Suleyman Yildirim

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
TKTanju Kapagan
Tanju Kapagan
NBNilufer Bulut
Nilufer Bulut
GEGokmen Umut Erdem
Gokmen Umut Erdem
SYSuleyman Yildirim
Suleyman Yildirim
ZEZeynep Betul Erdem
Zeynep Betul Erdem
HŞHalil Şahin
Halil Şahin
Angiosarcomas originating from the gastrointestinal tract are rare but highly aggressive tumors with poor prognosis. These tumors can be misdiagnosed as benign and malignant gastrointestinal tract lesions. The definitive histological diagnosis of angiosarcomasis made by pathologists based on immunohistochemical analysis demonstrating cluster of differentiation 31 (CD31), factor VIII-related antigen (FVIIIRAg), erythroblast transformation specific related gene (ERG), and cluster of differentiation 34 (CD34). Angiosarcomas are treated with a single or multimodality approach that may include resection, radiotherapy, chemotherapy, and palliative care, depending on the stage of disease and the condition of the patient. No matter the treatment option, metastasis and death rates are substantially highin patients with angiosarcoma. In this context, a 59-year-old male with synchronous double primary angiosarcoma arising from the gastric and rectum who presented with the complaint of abdominal pain and distention to the outpatient clinic is presented in this case report, along with a brief literature review.

8 June 2013 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
DSDede Sit
Dede Sit
TBTaner Basturk
Taner Basturk
SYSuleyman Yildirim
Suleyman Yildirim
FKFerdi Karagoz
Ferdi Karagoz
NBNalan Bozkurt
Nalan Bozkurt
AGAyşegül Gunes
Ayşegül Gunes

1 March 2017 in The Journal of Applied Laboratory Medicine
Verified
Journal Article
Closed access
PDF file
HSHakan Sarı
Hakan Sarı
BEBennur Esen
Bennur Esen
SYSuleyman Yildirim
Suleyman Yildirim
SPSaadet Pilten
Saadet Pilten
Hasan AydinHasan Aydin
Hasan Aydin
Background: α-Hydroxybutyrate (α-HB) is a marker of insulin resistance (IR) and lipid oxidation, both of which precede the development of diabetes and cardiovascular disorders. We aimed to analyze the relation of α-HB levels with anthropometric measurements in individuals without metabolic risk factors. Methods: A total of 82 nonobese individuals [body mass index (BMI) <30 kg/m2] without an accompanying chronic disorder were enrolled into the study. The entire cohort of participants underwent physical examination. Biochemical and hormonal parameters were analyzed. The BMI was calculated as weight/height2 (kg/m2). An ELISA method was used to analyze serum α-HB level. The relation of variables was analyzed by correlation analysis. Results: The mean age, BMI, body fat ratio, and waist/hip ratio of participants were 36 (9) years, 24.9 (2.2), 39.2 (3.9), and 0.82 (0.06), respectively. The mean fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR) levels, total cholesterol, triglyceride, HDL, and LDL levels were 90.7 (5.1) mg/dL, 9.8 (1.5) IU/mL, 2.2 (0.3), 193.2 (32.6) mg/dL, 119.3 (60.3) mg/dL, 54.6 (12.2) mg/dL, and 114.2 (30.4) mg/dL, respectively. Serum α-HB level was significantly correlated with age, BMI, body fat ratio, waist circumference, waist/hip ratio, fasting glucose, insulin, HOMA-IR, HDL, total cholesterol, and triglyceride. Conclusions: Serum α-HB, a strong marker of insulin resistance, is well correlated with deterioration of anthropometric parameters such as an increase in BMI and body fat distribution in patients with low diabetes risk.

6 September 2022 in Acta Cytologica
Verified
Journal Article
Closed access
PDF file
OBOguz Kagan Bakkaloglu
Oguz Kagan Bakkaloglu
NKNuray Kepil
Nuray Kepil
SYSuleyman Yildirim
Suleyman Yildirim
KAKadri Atay
Kadri Atay
MTMurat Tuncer
Murat Tuncer
YEYusuf Erzin
Yusuf Erzin
Introduction: Demonstration of diagnostic contribution of Papanicolaou Society of Cytopathology-standardized nomenclature for pancreaticobiliary cytology (PSC-PC) in endoscopic ultrasonography (EUS) fine-needle biopsy (FNA) biopsies is important for widespread use and further development. Methods: 179 EUS-FNA biopsies (89: solid, 90: cystic) and PSC-PC categories were compared with surgical definite histopathology and definite clinical diagnosis. Overall risk of malignancy (oROM) was calculated for each PSC-PC category. Diagnostic accuracy was evaluated. Results: The cytopathology of lesions was nondiagnostic in 27%. Ductal dilatation, lymphadenopathy, and solid characteristic (independently) were associated with diagnostic result, while lesion size was not. PSC-PC categories had 89% diagnostic consistency with surgical definite histopathology. Category mismatch was detected in 3 patients (11%), of which 2 had adenocarcinoma. oROM was 14.3% for nondiagnostic group, 46% for cat. III (atypia), and 12% for cat. IVB (neoplastic – other). In terms of malignancy, the PSC-PC system had 100% specificity; PPV, 92% sensitivity, and 81% NPV; and the diagnostic accuracy was 94%. Conclusion: Using PSC-PC in EUS-FNA biopsies, pancreatic malignancy can be diagnosed with high diagnostic accuracy. In mucinous cystic lesions, some malignancies may be missed. To predict the malignancy risk of cat. IVB, assessment of dysplasia seems important. Although PSC-PC is not the only parameter in terms of diagnosing malignancy, its contribution to the clinical decision is quite high.

1 December 2022 in Bagcilar Medical Bulletin
Verified
Journal Article
Closed access
ESEmel Saglam
Emel Saglam
Bennur EsenBennur Esen
Bennur Esen
SYSultan Yurtsever
Sultan Yurtsever
HKHande Karagedik
Hande Karagedik
SPSaadet Pilten
Saadet Pilten
DŞDede Şit
Dede Şit

15 May 2022 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
ASAbdullah Sonsuz
Abdullah Sonsuz
SBSelma Bozcan
Selma Bozcan
AHALI IBRAHIM HATEMI
ALI IBRAHIM HATEMI
SÖSebati Özdemir
Sebati Özdemir
BCBillur Canbakan
Billur Canbakan
MAMuhlis Cem Ar
Muhlis Cem Ar
Background: Hepatitis C is one of the leading causes of death in patients with inherited bleeding disorders. Currently, direct-acting antiviral drugs used for the treatment of hepatitis C have become an effective and a reliable option for people with inherited bleeding disorders. The aim of this study is to report the efficacy and safety of ombitasvir + paritaprevir/ritonavir and dasabuvir combination in the treatment of hepatitis C in patients with inherited bleeding disorders. Methods: In this retrospective study, we evaluated the efficacy and safety of the combination of ombitasvir + paritaprevir/ritonavir and dasabuvir in 10 adult patients with hemophilia A, 4 patients with hemophilia B, and 1 patient with von Willebrand disease who were infected with hepatitis C genotype 1. Results: Five patients had genotype 1a and 10 patients had genotype 1b chronic hepatitis C. One patient had Child A cirrhosis, 14 patients had chronic hepatitis C without cirrhosis. Hepatitis C virus ribonucleic acid was negative in all patients at week 4 and at the end of the treatment. Sustained virologic response was obtained in all patients. Serious side effects were detected in 3 patients, which were intra- muscular bleeding, erosive gastritis-related gastrointestinal bleeding, and pneumonia. Conclusion: Ombitasvir + paritaprevir combined with ritonavir and dasabuvir ± ribavirin is an effective treatment for patients infected with genotype 1 hepatitis C who have coagulation disorders. Tolerance and side effects are similar to other treatment options. Cite this article as: Sonsuz A, Bozcan S, Hatemi İ, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin combinations in patients with genotype 1 hepatitis C and inherited bleeding disorders. Turk J Gastroenterol. 2022;33(5):414-420.